Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
Want to see RIGL full AI Analyst Report?
RIGL Stock Chart & Stats
$32.43
-$0.99(-5.79%)
At close: 4:00 PM EST
$32.43
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$18.14 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)404.40K
Market Cap
$536.75M
Enterprise Value$558.05M
Total Cash (Recent Filing)$146.68M
Total Debt (Recent Filing)$45.72M
Price to Earnings (P/E)14.4
Beta1.95
Next Earnings
Aug 04, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.07
Shares Outstanding18,502,080
10 Day Avg. Volume502,012
30 Day Avg. Volume404,399
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda4.25
Forecast
1Y Price Target
$54.00Price Target Upside66.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)3.99
Revenue Forecast (FY)$282.83M
Bulls Say, Bears Say
Bulls Say
Clinical DataDurable clinical benefit for Gavreto and higher observed overall survival in U.S. patients support a potential U.S. commercial advantage versus competing RET inhibitors.
Earlier‑line AdoptionStronger survival in treatment‑naïve patients supports use of Gavreto in earlier treatment lines, potentially expanding the addressable market and boosting uptake.
Pipeline ProgressionAdvancement of R289 into dose expansion with planned dose selection and an FDA meeting, alongside initiation of a Phase 2 study in IDH1‑mutant high‑grade glioma, supports ongoing pipeline progression toward registrational goals.
Bears Say
Clinical And Funding RiskFailed or inconclusive clinical trials or inability to secure adequate funding could prevent the stock from reaching the analyst's price target.
Earnings QualityReported earnings were boosted by a large non‑cash deferred tax benefit, creating a notable gap versus operational expectations and raising questions about earnings sustainability.
Tax Accounting ImpactRecording federal and state income tax expenses through the income statement each quarter is expected to reduce accounting net income and earnings per share, increasing volatility in reported results.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $18.14 and its highest was $52.24 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $536.75M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 70 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on May 05, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.795 by -$0.355.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 18,502,080 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $0.44 in its last earnings report, missing expectations of $0.795. Following the earnings report the stock price went down -5.055%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$54.00 (66.51% Upside)
$54.00 (66.51% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.03%
12-Months-Change
Fundamentals
Return on Equity
147.03%
Trailing 12-Months
Asset Growth
186.75%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$54.00
▲(66.51% Upside)
Technical Analysis
Ownership Overview
3.28% Insiders
28.80% Mutual Funds
17.75% Other Institutional Investors
26.89% Public Companies and Individual Investors